SenzaGen Investor Relations Material
Latest events
Q1 2024
SenzaGen
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from SenzaGen
Access all reports
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers modified human cell lines that can be induced to react with a wide variety of chemicals and cell genes that may be activated by specific substances. SenzaGen AB was incorporated in 2000 and is based in Lund, Sweden. As of February 19, 2016, SenzaGen AB operates as a subsidiary of Ascendis Pharma A/S.
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
SENZA
Country
đžđȘ Sweden